Sipomid® (Siponimod)

Faxibet plus® ER (Dapagliflozin/Metformin)

Teriflunomide

The recommended dose of Teriflunomide is 7 mg or 14 mg orally once daily. Teriflunomide can be taken with or without food.

TOFAXEL® (Tofacitinib)

Tofacitinib is a Janus kinase (JAK) inhibitor. JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence ...

Faxibet® (Dapagliflozin)

Dapagliflozin is a Sodium-glucose cotransporter 2 (SGLT2) inhibitor. Dapagliflozin reduces reabsorption of filtered glucose and increases urinary glucose excretion. Dapagliflozin also reduces sodium r...

Rizolung® (Crizotinib)

Crizotinib is an inhibitor of receptor tyrosine kinases including ALK, HGFR, c-Met, ROS1, and RON. 

Encastry® (enzalutamide)

Enzalutamide is an androgen receptor inhibitor. Enzalutamide decreased proliferation and induced cell death of prostate cancer cells in vitro, and decreased tumor volume in animal model.

Vandesa® (Vandetanib)

In vitro studies have shown that vandetanib inhibits the tyrosine kinase activity of the EGFR and VEGFR families, RET, BRK, TIE2, and members of the EPH receptor and Src kinase families. These recepto...

Simerta® (Osimertinib)

Simerta ® is a kinase inhibitor of epidermal growth factor receptor (EGFR) which binds irreversibly to certain mutant forms of EGFR (T790M, L858R, and exon 19 deletions). ...

Palbobrest® (Palbociclib)

Palbociclib is an inhibitor of cyclin-dependent kinases (CDK) 4 and 6. Cyclin D1 and CDK4/6 are downstream of signaling pathways which lead to cellular proliferation.

Dasanib® (Dasatinib)

Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. Based on modeling studies, Dasatinib is predicted to bi...

Kimotar® (Erlotinib)

Kimotar® inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor. Kimotar® expressed on the cell surface of healthy cells and cancer ...